Figure 3.

Human AML cell lines are sensitive to ZEB2 inhibition. (A) Box plot showing mRNA expression levels of ZEB1 and ZEB2 in CCLE³ cell lines, comparing AML cell lines vs non-AML cancer cell lines. ***P < .001; n.s., not significant, t test. (B) shRNA fold depletions of ZEB2 shRNAs in the human cell line screen. ***P < .001; n.s., not significant, PARIS analysis.⁹ (C) ZEB2 expression in hematopoiesis²⁵ and AML.⁴ Error bars indicate 5% to 95% percentile. (D) Immunoblotting of ZEB2 at day 6 after shRNA lentivirus infection. (E) Viability of AML cells after ZEB2 knockdown. Error bars, standard deviation (SD) (n = 3). (F) Competitive proliferation assays of AML cells infected with ZEB2 shRNA (ZEB2-531) and its seed control (ZEB2-531-sc). Graph shows normalized cell number as a percentage of the first time point (4 days after infection). Error bars, SD (n = 3). AML_Complex, complex karyotype; AML_Normal, normal karyotype; CMP, common myeloid progenitor cell; GMP, granulocyte monocyte progenitors; HSC, hematopoietic stem cell; Luc, shRNA targeting firefly luciferase; MDS, myelodysplastic syndrome; MEP, megakaryocyte-erythroid progenitor cell; MPP, multipotential progenitors; PM, promyelocyte; PMN, polymorphonuclear cells; ZEB2-382, shRNA targeting ZEB2.